BiotechTube
Home/Pipeline/Hemlibra (emicizumab)

Hemlibra (emicizumab)

Hemophilia A

ApprovedCommercial

Key Facts

Indication
Hemophilia A
Phase
Approved
Status
Commercial
Company
Chugai Pharmaceutical

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd. is Japan's premier biotechnology company and a subsidiary of Roche, focusing on precision medicine and innovative drug development. Founded in 1925, the company has built a strong portfolio in oncology, autoimmune diseases, and rare conditions through both in-house R&D and strategic partnerships with Roche. Chugai operates as Roche's key development and commercialization hub in Japan while maintaining its independent research capabilities and Tokyo Stock Exchange listing.

View full company profile

Therapeutic Areas

OncologyAutoimmune DiseasesRare DiseasesHematologyNeurology

Other Hemophilia A Drugs

DrugCompanyPhase
Factor VIII ProductsCSLCommercial
Gene TherapyBioMarin PharmaceuticalCommercial
Human Coagulation Factor VIIIShanghai RAAS Blood ProductsApproved
Recombinant Coagulation Factor VIIIShanghai RAAS Blood ProductsPhase 3
Factor VIIITiantan BioApproved
Recombinant Factor VIIIHualan Biological EngineeringPre-clinical
Giroctocogene fitelparvovec (SB-525)Sangamo TherapeuticsPhase 3